Antibiotic-Associated Diarrhea
Antibiotic-Associated Diarrhea (AAD) is characterized by the passing of loose, watery stools more than three times per day after antibiotic treatment, occurring in about 1 in 5 people. It results from an imbalance in colonic microbiota, altering carbohydrate metabolism and decreasing short-chain fatty acid absorption, and may also involve overgrowth of pathogenic organisms like Clostridium difficile.
Health Outcomes
- Accelerated Diarrhea Recovery
- Accurate Enumeration of Viable Probiotic Bacteria
- Adjusted Intestinal Microbiota Abundance
- Alleviated Diarrhea
- Altered Bacterial Proportions
- Altered Bifidobacterial Population
- Altered Colonic Microbial Communities
- Altered Dominant Intestinal Bacterial Composition
- Altered Enteric Bacterial Flora
- Altered Faecal Microbiota Profile
- Altered Gastrointestinal Health Post-Infection
- Altered Gastrointestinal Microbial Communities
- Altered Gastrointestinal Microbiome Composition
- Altered Gut Microbial Community
- Altered Microbial Population Composition
- Altered Stool Microbiota Profile
- Association with Serious Adverse Events
- Attenuated Gut Dysbiosis
- Carriage of Toxin-Producing Clostridium Difficile
- Changed Stool Consistency
- Confirmed Safety of Oral Probiotic Administration
- Decreased Abundance of Lactobacillaceae
- Decreased Stool pH
- Delayed Onset of First Diarrhea Episode
- Disrupted Gut Microbiota Distribution
- Effective Gastroenteritis Treatment
- Effectiveness Compared to Commercial Probiotic
- Enhanced Beneficial Bacteria in Intestinal Microbiota
- Enhanced Colon Bacterial Diversity
- Enhanced Gut Microbiome Health
- Enhanced Gut Microbiota Diversity
- Enhanced Gut Microbiota Stability
- Enhanced Gut Probiotic Bacteria Propagation
- Enhanced Intestinal Defense Maturation
- Enhanced Intestinal Lactobacillus Community
- Enhanced Intestinal Microbiota Maturation
- Enhanced Microbiota Recovery
- Enhanced Pathogen Protection
- Enhanced Probiotic Activity
- Enhanced Probiotic Presence
- Gut Localization of Lactobacillus brevis
- Healthy Gut Microbiome
- High Viability of Probiotic Lactobacillus crispatus BC4 in Cheese
- Improved Antibiotic-Associated Diarrhea
- Improved Beneficial Intestinal Bacteria
- Improved Beneficial Intestinal Microbiota
- Improved Bifidobacterium-Dominated Microbiota
- Improved Bowel Habits
- Improved Bristol Stool Score
- Improved Colonization Resistance
- Improved Colonization Resistance to Pathogens
- Improved Colonization of Gastrointestinal Tract by Lactobacilli
- Improved Diarrhea Symptoms
- Improved Efficacy of Diarrhea Treatment
- Improved Fecal Lactobacillus Count
- Improved Fecal Microbiota
- Improved Fecal Microbiota Diversity
- Improved Fecal Score
- Improved Functional Diarrhea Symptoms
- Improved Gastrointestinal Microbiome Balance
- Improved Gastrointestinal Pathogen Inhibition
- Improved Growth of Beneficial Bacteria
- Improved Gut Bacterial Diversity
- Improved Gut Barrier Function
- Improved Gut Comfort
- Improved Gut Flora Modulation
- Improved Gut Health (Lower Faecal pH)
- Improved Gut Microbiome Composition
- Improved Gut Microbiota Balance
- Improved Gut Microbiota Distribution
- Improved Gut Microbiota Homeostasis
- Improved Gut Microflora
- Improved Gut Protection
- Improved Host-Probiotic Interaction
- Improved Identification of Bacillus clausii
- Improved Infant Gut Microbiota Restoration
- Improved Intestinal Cell Integrity
- Improved Intestinal Defense Mechanism
- Improved Intestinal Epithelial Barrier
- Improved Intestinal Flora
- Improved Intestinal Flora Diversity
- Improved Intestinal Microbiota
- Improved Intestinal Microbiota Balance
- Improved Intestinal Microbiota Health
- Improved Intestinal Microflora
- Improved Intestinal Microflora Balance
- Improved Intestinal Microflora Diversity
- Improved Lactobacillus Abundance
- Improved Management of Acute Gastroenteritis
- Improved Management of Antibiotic-Related Diarrhea
- Improved Management of Colitis
- Improved Management of Diarrhea
- Improved Microbiota Activity
- Improved Microbiota Diversity
- Improved Niche Colonization
- Improved Probiotic Function
- Improved Probiotic Product Stability
- Improved Probiotic Safety
- Improved Probiotic Suitability
- Improved Recovery from Diarrhea
- Improved Recovery of Intestinal Flora
- Improved Resistance to Infections
- Improved Resistance to Intestinal Pathogens
- Improved Response to Prebiotics
- Improved Short-Chain Fatty Acid Production
- Improved Stability of Gut Microbiota
- Improved Stool Consistency
- Improved Survival of Probiotic Bacteria
- Improved Survival of Probiotic Strains During Antibiotic Use
- Improved Tolerability of Bifidobacterium breve BBG-01
- Improved Tolerability of Bifidobacterium lactis HN019
- Improved Tolerance to High Doses of Probiotics
- Improved Treatment Safety
- Incidence of Hospital-Acquired Diarrhea
- Increase in Beneficial Bifidobacterial Species
- Increased Abdominal Symptoms in Children Taking Antibiotics
- Increased Abundance of Bifidobacterium animalis
- Increased Adverse Effect
- Increased Adverse Effects
- Increased Adverse Reactions
- Increased Antibacterial Compound Production
- Increased Bacillus Species Populations
- Increased Beneficial Bacterial Colonization
- Increased Beneficial Bacterial Counts
- Increased Beneficial Gut Microbiota Abundance
- Increased Beneficial Intestinal Metabolites
- Increased Beneficial Intestinal Microorganisms
- Increased Bifidobacteria Levels
- Increased Bifidobacteria in Colon
- Increased Bifidobacteria in Intestinal Microbiota
- Increased Bifidobacterial Development
- Increased Bifidobacterial Populations in Feces
- Increased Bifidobacterium Concentration
- Increased Bifidobacterium Dominance in Faecal Microbiota
- Increased Bifidobacterium Levels
- Increased Bifidobacterium Persistence Duration
- Increased Bifidobacterium animalis Level
- Increased Bifidobacterium lactis Proliferation in the Intestine
- Increased Bifidobacterium-Dominated Gut Microbiota
- Increased Cecal Lactobacilli Levels
- Increased Colon Lactobacilli
- Increased Colonic Lactobacilli Levels
- Increased Cultivable Lactobacilli
- Increased Defecation Frequency
- Increased Diarrhea Incidence
- Increased Diarrhoea-Free Rate in Children After 72 Hours
- Increased Digestive Problem
- Increased Endogenous Bifidobacteria Levels
- Increased Fecal Acidity Similar to Breastfed Infants
- Increased Fecal Bifidobacteria
- Increased Fecal Bifidobacterium breve Levels
- Increased Fecal Excretion
- Increased Fecal Lactic Acid Bacteria Concentration
- Increased Fecal Lactic Acid Bacteria Counts
- Increased Fecal Lactic Acid Concentration
- Increased Fecal Lactobacilli Content
- Increased Fecal Lactobacilli Levels
- Increased Fecal Lactobacilli Population
- Increased Fecal Lactobacilli Viability
- Increased Fecal Lactobacillus Paracasei Levels
- Increased Fecal Lactobacillus reuteri Concentration
- Increased Fecal Lactobacillus reuteri Levels
- Increased Fecal Moisture Content
- Increased Fecal Output
- Increased Fecal Probiotic Bacteria
- Increased Fecal Probiotic Strains
- Increased Fecal Score
- Increased Frequency of Loose or Watery Stools
- Increased Gastrointestinal Discomfort
- Increased Gastrointestinal Tract Colonization
- Increased Gut Bifidobacterium Count
- Increased Gut Microbial Supplementation
- Increased Interest in Probiotic Supplements
- Increased Intestinal Bifidobacteria
- Increased Intestinal Bifidobacteria Levels
- Increased Intestinal Bifidobacteria Population
- Increased Intestinal Lactic Acid Bacteria Count
- Increased Intestinal Lactic Acid Bacteria Population
- Increased Intestinal Lactobacilli Counts
- Increased Intestinal Lactobacillus sakei Levels
- Increased Intestinal Motility
- Increased Lactic Acid Bacteria Levels
- Increased Lactobacilli Colonization in the Gut
- Increased Lactobacillus Population
- Increased Levels of Bifidobacterium infantis in Feces
- Increased Microbial Viability in Human Gut
- Increased Microbiota Engraftment
- Increased Population of Beneficial Gut Bacteria
- Increased Probiotic Activity
- Increased Probiotic Bacteria Abundance
- Increased Probiotic Bacteria Colonization
- Increased Probiotic Bacterial Count
- Increased Probiotic Bacterial Survival Through Upper Gastrointestinal Transit
- Increased Probiotic Co-existence
- Increased Probiotic Concentration in Stool
- Increased Probiotic Genus Proportion
- Increased Probiotic Levels
- Increased Probiotic Potential
- Increased Probiotic Tolerance
- Increased Proliferation of Administered Bifidobacteria
- Increased Protective Fecal Bifidobacteria
- Increased Protective Fecal Bifidobacterial Diversity
- Increased Relative Abundance of Beneficial Microbiota (Lactobacillus)
- Increased Resistance to Simulated Gastrointestinal Conditions
- Increased Short-Chain Fatty Acid-Producing Bacteria
- Increased Short-Chain Fatty Acids Formation
- Increased Specific Probiotic Strains
- Increased Stool Frequency
- Increased Stool Looseness
- Increased Stool Volume
- Increased Tolerance to Gastrointestinal Conditions
- Increased Viable Bifidobacteria Counts
- Lack of Long-Term Colonization of Bifidobacteria Strains
- Maintained Fecal Short Chain Fatty Acid Levels
- Maintained Gut Microbiota Stability
- Maintained Healthy Gut Environment
- Maintained Intestinal Barrier Function
- Maintained Intestinal Microbial Abundance
- Maintained Intestinal Microbiota Balance
- Maintained Intestinal Microbiota Stability
- Maintained Normal Intestinal Microbiota
- Maintained Prevotella-Dominant Gut Microbiota
- Maintained Short-Chain Fatty Acid Levels During Antibiotic Treatment
- Maintenance of Therapeutic Probiotic Levels
- Managed Gut Microbiota Disturbance
- Microbiome Remodeling
- Minor Adverse Effects
- Mitigated Microbiota Changes
- Moderate Impact on Main GI Bacterial Groups
- Modification of Gastrointestinal Microbiome
- Modified Fecal Microbiota
- Modulated Gastrointestinal Microbiota
- Modulated Gut Microbiota
- Modulated Intestinal Microbial Community
- Modulation of Microbiota Activity
- No Change in Diarrhea Development in C. difficile-Positive Patients
- No Change in Diarrhea Duration
- No Change in Mouse Intestinal Flora Composition
- No Demonstrated Efficacy for Isolated Bifidobacterium Use
- No Impact on Negative Mood States
- No Reduction in Gastrointestinal Infections
- Normalized Intestinal Microbiota
- Normalized Stool Consistency
- Normalized Stool Type
- Partial Restoration of Intestinal Microbiota
- Potential Probiotic Benefits
- Potential Probiotic Health Effects
- Potentially Effective Antibacterial Proteins
- Presence of Lactobacillus salivarius CECT5713 in Feces
- Presence of Viable L. acidophilus La-5 Strains in Feces
- Preserved Endogenous Bifidobacteria Composition
- Preventative Gut Colonisation
- Prevention of Antibiotic-Associated Diarrhea
- Prevention of C. difficile-Induced Diarrhea
- Prevention of Diarrhea
- Prevention of Intestinal Dysbiosis
- Prevention of Intestinal Infections
- Probiotic Adherence Variability Based on Host Factors
- Protection of Colonic Mucosa from C. difficile Toxins
- Recovered Microbiome-associated Dysbiosis
- Reduced Abundance of Harmful Bacteria
- Reduced Abundance of Pathobionts
- Reduced Adhesion of Diarrheagenic Bacteria
- Reduced Adverse Event
- Reduced Adverse Reaction
- Reduced Antibiotic Damage to Microbiota
- Reduced Antibiotic-Associated Diarrhea Symptoms
- Reduced Antibiotic-Associated Diarrhoea in Children
- Reduced Antibiotic-Associated Gastrointestinal Complaints
- Reduced Antibiotic-Associated Gut Microbiome Disruption
- Reduced Antibiotic-Associated Side Effects in Helicobacter pylori Infection
- Reduced Antibiotic-Induced Gut Dysbiosis
- Reduced Antimicrobial Use
- Reduced Bifidobacterial Population
- Reduced Clostridioides difficile Abundance
- Reduced Clostridioides difficile Infection
- Reduced Clostridium Difficile Adherence
- Reduced Clostridium Difficile Growth
- Reduced Clostridium Difficile Levels
- Reduced Clostridium Difficile in Intestines
- Reduced Clostridium Species Counts
- Reduced Clostridium difficile Count
- Reduced Clostridium difficile Infection
- Reduced Colonic Clostridium Species
- Reduced Colonic Transit Time
- Reduced Colonization by Diarrheagenic E. coli (EPEC)
- Reduced Colonization of Aeromonas Hydrophila in the Intestine
- Reduced Colonization with Probiotic Lactobacilli
- Reduced Days with Diarrhea
- Reduced Diarrhea
- Reduced Diarrhea Duration
- Reduced Diarrhea Episodes
- Reduced Diarrhea Frequency
- Reduced Diarrhea Incidence
- Reduced Diarrhea Incidence in Day Care Centers
- Reduced Diarrhea Incidence in Offspring
- Reduced Diarrhea Recurrence
- Reduced Diarrhea Severity
- Reduced Diarrhea Symptoms
- Reduced Drug-Induced Enteropathy
- Reduced Drug-Induced Intestinal Damage
- Reduced Duration of Acute Diarrhoea
- Reduced Duration of Acute Gastroenteritis
- Reduced Duration of Anti-TB-associated Gastrointestinal Symptoms
- Reduced Duration of Antibiotic Usage
- Reduced Duration of Antibiotic-Associated Diarrhea
- Reduced Duration of Diarrhea
- Reduced Duration of Diarrhea Episodes
- Reduced Duration of Diarrhea Symptoms
- Reduced Dysbiosis
- Reduced Dysbiosis-Associated Bacteria Growth
- Reduced E. coli Adherence in Gut
- Reduced Enterobacteriaceae Counts
- Reduced Enterococci Levels
- Reduced Enteropathogen Adhesion
- Reduced Enteropathogen Presence in Enterocyte Layer
- Reduced Enteropathogenic Bacteria
- Reduced Enterotoxicity
- Reduced Faecal Clostridium Population
- Reduced Faecal pH
- Reduced Fecal Clostridium Levels
- Reduced Fecal Clostridium difficile
- Reduced Fecal Coliform Count
- Reduced Fecal Enterobacilli
- Reduced Fecal Enterococci
- Reduced Fecal Escherichia coli Levels
- Reduced Fecal Excretion of Pathogenic Bacteria
- Reduced Fecal Microbiota Diversity
- Reduced Fluctuations in Intestinal Bacteria
- Reduced Gastrointestinal Adverse Event
- Reduced Gastrointestinal Adverse Events
- Reduced Gastrointestinal Coliforms
- Reduced Gastrointestinal Disease Incidence in Children
- Reduced Gastrointestinal Infections
- Reduced Gastrointestinal Symptom Severity
- Reduced Growth of Putrefactive Bacteria
- Reduced Hard Stool
- Reduced Harmful Bacteria in Intestinal Microbiota
- Reduced Harmful Gut Bacteria
- Reduced Harmful Intestinal Bacteria
- Reduced Hospitalization for Acute Gastroenteritis
- Reduced Human Infections
- Reduced Incidence of Acute Colitis
- Reduced Incidence of Acute Diarrhoea
- Reduced Incidence of Antibiotic-Associated Diarrhea
- Reduced Incidence of Chronic Diarrhea
- Reduced Incidence of Clostridium Difficile Infection
- Reduced Incidence of Diarrhea in Pigs
- Reduced Incidence of Gastroenteritis
- Reduced Incidence of Gastrointestinal Tract Infection Symptoms
- Reduced Incidence of Loose Stools
- Reduced Incidence of Loose or Watery Stools
- Reduced Infectious Complication
- Reduced Initial Mild Diarrhea
- Reduced Intestinal Infections
- Reduced Intestinal Inflammation Severity
- Reduced Intestinal Pathogen Load
- Reduced Lactobacillus Counts
- Reduced Levels of C. perfringens
- Reduced Microbial Load
- Reduced Nontransferable Antibiotic Resistance
- Reduced Nosocomial Diarrhea Incidence
- Reduced Odds of Probiotic Lactobacilli Successful Colonization
- Reduced Pathogen Association
- Reduced Pathogenic Bacteria in Gut
- Reduced Pathogenic Bacterial Colonization
- Reduced Pathogenic Bacterial Load In Vivo
- Reduced Pathogenicity of Escherichia coli
- Reduced Potential Pathogens
- Reduced Prolonged Diarrhea
- Reduced Recovery Time for Diarrhea
- Reduced Recurrent Clostridioides Difficile Infection
- Reduced Recurrent Clostridioides difficile Infection Incidence
- Reduced Risk of Clostridium Difficile-Associated Diarrhea
- Reduced Risk of Diarrhea
- Reduced Salmonella Translocation
- Reduced Secretory IgA Content in Faeces
- Reduced Severity of Gastroenteritis
- Reduced Side Effect
- Reduced Stool pH
- Reduced Time Spent for Defecation
- Reduced Time to First Formed Stool
- Reestablished Intestinal Microecology
- Regulated Colonic Bacterial Flora
- Regulated Intestinal Barrier Function
- Regulated Intestinal Microbiota Balance
- Regulated Intestinal Microorganisms
- Regulated Microbiota Function
- Resolution of Diarrhea
- Resolved Moderate Diarrhea
- Restored Endogenous Microbiota Equilibrium
- Restored Gut Microbiome Balance
- Restored Gut Microbiota
- Restored Gut Microbiota Homeostasis
- Restored Intestinal Microbiota Balance
- Restored Microbial Diversity
- Restored Microbiome Composition
- Restored Normal Microbiota
- Restored Relative Abundance of Specific Bacteria
- Restored Short-Chain Fatty Acid Levels
- Safety in Terms of Adverse Events
- Safety in Treatment for Bacterial Vaginosis
- Shortened Diarrhea Duration
- Similar Rate of Diarrhea
- Stabilized Fecal Microbiota
- Stabilized Gut Microbiota
- Stabilized Intestinal Microbiota
- Stable Adverse Drug Reaction Rate
- Stable Antibiotic Susceptibility Profiles
- Successful Gastrointestinal Tract Colonization
- Successful Gut Colonization
- Temporary Intestinal Dominance of Lactobacillus paracasei A
- Transient Gut Colonization
- Transient Increase in Intestinal Lactobacillus Populations
- Unchanged Cell Numbers of Fecal Bacteria
- Unchanged Diarrhea Rate
- Unchanged Incidence of Diarrhea
- Unchanged Intestinal Bacterial Concentrations
- Unchanged Severe Diarrhea
- Unchanged Use of Antibiotics
- Viability of Probiotic Bacteria in Cheese
- Well Tolerated Probiotic
- Worsened Fecal Scores